Cargando…
Pancreatitis cytosorbents (CytoSorb) inflammatory cytokine removal: A Prospective Study (PACIFIC)
BACKGROUND: Acute pancreatitis (AP) usually has a mild course with a mortality rate below 1%. However, around 10% of patients develop severe AP (SAP) involving extra-pancreatic tissues and other organ systems. The mortality of SAP is around 42%. The outcome of SAP is closely related to the developme...
Autores principales: | Huber, Wolfgang, Algül, Hana, Lahmer, Tobias, Mayr, Ulrich, Lehmann, Miriam, Schmid, Roland M., Faltlhauser, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358351/ https://www.ncbi.nlm.nih.gov/pubmed/30681551 http://dx.doi.org/10.1097/MD.0000000000013044 |
Ejemplares similares
-
CytoSorb-friend or foe!!
por: Pattnaik, Saroj Kumar, et al.
Publicado: (2015) -
CytoSorb removes MDMA in vitro, but is it an effective therapy in vivo?
por: Honore, Patrick M., et al.
Publicado: (2020) -
Impact of CytoSorb® on interleukin-6 in cardiac surgery
por: Geisler, Daniela, et al.
Publicado: (2023) -
Prevention of vasoplegia with CytoSorb in heart failure patients undergoing cardiac surgery (CytoSorb-HF trial): protocol for a randomised controlled trial
por: Papazisi, Olga, et al.
Publicado: (2022) -
Hemoadsorption in the critically ill—Final results of the International CytoSorb Registry
por: Hawchar, Fatime, et al.
Publicado: (2022)